Rigel Pharmaceuticals (RIGL) Projected to Release Quarterly Earnings on Tuesday

Rigel Pharmaceuticals (NASDAQ:RIGL) is expected to be releasing its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect Rigel Pharmaceuticals to post earnings of $0.1297 per share and revenue of $55.2750 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Rigel Pharmaceuticals (NASDAQ:RIGL) last released its earnings results on Tuesday, May 5th. The biotechnology company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.80 by ($0.36). Rigel Pharmaceuticals had a return on equity of 47.99% and a net margin of 121.50%.The company had revenue of $58.82 million for the quarter, compared to analyst estimates of $62.40 million. On average, analysts expect Rigel Pharmaceuticals to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Rigel Pharmaceuticals Price Performance

Shares of NASDAQ RIGL opened at $37.75 on Tuesday. The stock’s 50-day moving average is $35.17 and its two-hundred day moving average is $33.09. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.62 and a quick ratio of 2.48. Rigel Pharmaceuticals has a 1-year low of $19.51 and a 1-year high of $52.24. The company has a market cap of $698.45 million, a price-to-earnings ratio of 2.01 and a beta of 1.14.

Insider Activity at Rigel Pharmaceuticals

In other news, Director Kamil Ali-Jackson sold 2,500 shares of the stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $35.00, for a total value of $87,500.00. Following the transaction, the director owned 10,125 shares in the company, valued at approximately $354,375. This represents a 19.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 10.47% of the company’s stock.

Institutional Investors Weigh In On Rigel Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Invesco Ltd. boosted its holdings in Rigel Pharmaceuticals by 24.1% in the fourth quarter. Invesco Ltd. now owns 34,921 shares of the biotechnology company’s stock valued at $1,496,000 after purchasing an additional 6,790 shares in the last quarter. VARCOV Co. acquired a new stake in Rigel Pharmaceuticals during the fourth quarter worth approximately $238,000. Verdad Advisers LP acquired a new stake in Rigel Pharmaceuticals during the fourth quarter worth approximately $372,000. Virtus Investment Advisers LLC acquired a new stake in Rigel Pharmaceuticals during the fourth quarter worth approximately $279,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Rigel Pharmaceuticals during the 4th quarter worth approximately $506,000. Hedge funds and other institutional investors own 66.23% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on RIGL. Citigroup reissued a “buy” rating and set a $81.00 price objective (up from $69.00) on shares of Rigel Pharmaceuticals in a research report on Wednesday, May 13th. Zacks Research downgraded shares of Rigel Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, May 7th. HC Wainwright reiterated a “buy” rating and set a $57.00 price target on shares of Rigel Pharmaceuticals in a report on Tuesday, June 2nd. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Rigel Pharmaceuticals in a research report on Friday, July 17th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $54.50.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel’s lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).